Tesofensine
Tesofensine is an investigational small-molecule monoamine reuptake inhibitor studied for weight management; it is not a peptide.
The short version
- Why people discuss it
- Discussed for appetite suppression and weight management; it is a small molecule rather than a peptide. Community interest does not establish benefit or a suitable treatment.
- What it is
- Tesofensine is an investigational small-molecule monoamine reuptake inhibitor studied for weight management; it is not a peptide.
- Biggest caution
- Trial findings belong to the studied formulation, dose, population and monitoring. They do not validate products sold online, and cardiovascular, neuropsychiatric and longer-term safety require source-specific review.
- Stack context
- Related profiles reflect adjacent community topics or biological context. They do not establish combination benefit, compatibility or a validated regimen.
Dose and frequency reference
Reference only — not a recommendation. Amounts describe source-specific community examples, selected study regimens or the named product label. They do not establish safety, effectiveness, product identity, or a suitable dose for any person. Never convert mg, mcg, or IU into syringe “units” without the exact product concentration.
Legacy community reference: no complete dosing regimen was independently corroborated by the two new source collections.
Oral
Community reference · Not clinical guidance- Amount
- 0.25 mg initiation; 0.5 mg commonly discussed
- Frequency
- Once daily
- Duration / phase
- 24-week study observation period; no established on/off cycle
Oral community and investigational study context. A trial observation period does not establish when to stop or repeat a community course. The new inbox sources do not independently corroborate this complete regimen. Reference only; this does not establish safety, effectiveness or individual suitability.
Reference source · reviewed 2026-09-12Evidence & sources · Community source profile
AxonRep synthesizes community discussion signals from its internal research corpus. Individual creator sources remain attributed to the synthesis; public reference sites used in the latest comparison are linked separately. The synthesis is not clinical evidence.
- AxonRep community research synthesisAxonRep synthesis · Checked 2026-09-12
- PubMed: randomized phase 2 tesofensine obesity trialExisting research · Checked 2026-09-12